Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 501–600 of 1,010
Ayoub, S., Arabi, M., Al-Najjar, Y. A., Laswi, I., Outeiro, T. F., & Châari, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05051-9 · Cited by 27
“This disruption, driven by kinase dysregulation, oxidative stress, and inflammation, correlates closely with dementia severity [11, 12].”
Mitochondrial dysfunction: Related diseases, influencing factors, and detection
Li, Z., Li, S., Chen, W., Zhang, Z., Pan, C., Peng, L., Cheng, C., Zhu, J., Sun, H., & Dai, Z. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20250005 · Cited by 25
Phthalocyanine compounds in electrochemical sensors
Turan, R., & Koca, A. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114176 · Cited by 22
Lanzillotta, S., Rolfi, L. R., Zulli, B., & Barone, E. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00144 · Cited by 25
“The role of GLP-1 in mitochondrial function is being studied extensively, as it may have implications for neurodegenerative diseases (Monti et al., 2022b).”
Chronic MC-LR exposure promoted Aβ and p-tau accumulation via regulating Akt/GSK-3β signal pathway
Ma, Y., Wang, J., Xu, D., Chen, Y., & Han, X. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.148732 · Cited by 24
Rosell‐Cardona, C., Amat, C., Griñán‐Ferré, C., Polo, J., Pallàs, M., Pérez‐Bosque, A., Moretó, M., & Miró, L. (2022) · Nutrients · doi:10.3390/nu14112211 · Cited by 25
“Although aging is the major risk factor for AD [4], many factors can influence its development, such as family history, susceptibility genes, and diet [5].”
BackgroundCritical appraisal on mitochondrial dysfunction in Alzheimer’s disease
Ahmad, F., & Sachdeva, P. (2022) · Aging Medicine · doi:10.1002/agm2.12217 · Cited by 23
LncRNA HOTAIR in exercise-induced neuro-protective function in Alzheimer’s disease
Lü, J., Liu, L., Chen, J., Zhi, J., Li, J., Li, L., & Jiang, Z. (2022) · Folia Neuropathologica · doi:10.5114/fn.2022.118961 · Cited by 23
“As a progressive neuro-degenerative disease, AD is characterized by multidomain cognitive dysfunction, including deterioration in thinking and independence [2].”
BackgroundKeighron, C. N., Avazzadeh, S., Goljanek‐Whysall, K., McDonagh, B., Howard, L., Ritter, T., & Quinlan, L. R. (2023) · Biomedicines · doi:10.3390/biomedicines11030728 · Cited by 22
Tracing the Path between Mushrooms and Alzheimer’s Disease—A Literature Review
Silva, A. M., Preto, M., Grosso, C., Vieira, M., Delerue-Matos, C. M., Vasconcelos, V. M., Reis, M. A., Barros, L., & Martins, R. F. (2023) · Molecules · doi:10.3390/molecules28145614 · Cited by 25
“The application of natural compounds is among the new features for therapies against AD, as described in recent reviews [25,35,36].”
BackgroundEmerging Roles of Cells and Molecules of Innate Immunity in Alzheimer’s Disease
Tamburini, B., Badami, G. D., Manna, M. P. L., Azgomi, M. S., Caccamo, N., & Dieli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511922 · Cited by 25
Peripheral inflammation is a potential etiological factor in Alzheimer’s disease
Li, Z., Wang, H., & Yin, Y. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0049 · Cited by 25
Current Advances in Mitochondrial Targeted Interventions in Alzheimer’s Disease
de Sousa, T. S., Moreira, P. I., & Cardoso, S. (2023) · Biomedicines · doi:10.3390/biomedicines11092331 · Cited by 24
“…from the extracellular deposition of amyloid β protein (A β ) and the intracellular accumulation of neurofibrillary tangles composed of hyperphosphorylated tau (pTau) protein, which could trigger the neurodegenerative cascade leading to the loss of neurons associated with higher brain function [4].”
Li, Z., Chen, Z., & Peng, J. (2023) · Journal of Neurogenetics · doi:10.1080/01677063.2023.2259995 · Cited by 22
“Other sub-stances, such as LPS, could also stimulate microglia activation, resulting in brain damage (Breijyeh & Karaman, 2020; Lin et al ., 2012; Mohr et al ., 2022).”
Simple model systems reveal conserved mechanisms of Alzheimer’s disease and related tauopathies
Jiang, Y., & MacNeil, L. T. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00664-x · Cited by 23
“It is characterized by the accumulation of amyloid-beta in senile plaques and hyperphosphorylated Tau in neurofibrillary tangles (NFTs) [22].”
BackgroundYadav, V. K., Choudhary, N., Gacem, A., Verma, R. K., Hasan, M. A., Imam, M. T., Almalki, Z. S., Yadav, K. K., Park, H.-K., Ghosh, T., et al. (2023) · Redox Report · doi:10.1080/13510002.2023.2269331 · Cited by 24
“Several literary works have evidenced that AD occurs due to a synergy, for instance, genetic susceptibility [203,204], aging [205], environment [206], occupation [207], and overexposure to metals [208,209].”
BackgroundJin, S., Guan, X., & Min, D. (2023) · Current Alzheimer Research · doi:10.2174/0115672050272577231120060909 · Cited by 23
“The disease is characterized by the accumulation of amyloid-beta (A β ) plaques and neurofibrillary tangles, leading to cognitive decline and functional impairment [3].”
Serotonin Receptors as a Potential Target in the Treatment of Alzheimer’s Disease
Eremin, D. V., Kondaurova, E. M., Rodnyy, A. Y., Molobekova, C. A., Kudlay, D. A., & Naumenko, V. S. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120064 · Cited by 25
“According to the amyloid hypothesis of AD pathogenesis, the imbalance between Aβ production and degradation is the key event leading to neurotoxicity and induction of pathological hyperphosphorylation of tau protein and, consequently, neurode-generation [27].”
Antioxidant and anti-Alzheimer's potential of Tetragonisca angustula (Jataí) stingless bee pollen
dos Santos, N. C. L., Malta, S. M., Franco, R. R., Silva, H. C. G., Silva, M. H., Rodrigues, T. S., de Oliveira, R. M., Araújo, T. N., Augusto, S. C., Espíndola, F. S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-51091-3 · Cited by 24
Francesco, M. A. D. (2024) · Viruses · doi:10.3390/v16010133 · Cited by 22
“This protein plays an important role in central nervous system (CNS) homeostasis because it is involved in synapsis, calcium homeostasis, metal ion capture, and neurogenesis [20].”
BackgroundHu, G., Jiang, X., Du, S., Zhang, K., & Chen, Z. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12797 · Cited by 23
Nanomodulators That Target Alzheimer’s Disease: A Review
Pradhan, N., & Jana, N. R. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c04846 · Cited by 24
Lutein and the Underlying Neuroprotective Promise against Neurodegenerative Diseases
Iyer, S., Bhat, I., & Sheshappa, M. B. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300409 · Cited by 22
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
Gu, Z., Lin, S., Yu, J., Jin, F., Zhang, Q., Xia, K., Chen, L., Li, Y., & He, B. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116571 · Cited by 24
MicroRNAs and synapse turnover in Alzheimer’s disease
Dalal, S., Ramirez-Gomez, J., Sharma, B., Devara, D., & Kumar, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102377 · Cited by 26
Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100675 · Cited by 25
Liang, Z., Li, X., Luo, X., Luo, H.-J., Chen, Y., Cai, M., Zhong, X.-X., Fang, Y., Guo, T., Shi, Y., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.02.018 · Cited by 23
Yu, Q.-S., Feng, W.-Q., Shi, L., Niu, R., & Liu, J. (2022) · Brain Sciences · doi:10.3390/brainsci12081022 · Cited by 24
Mohamed, S. M., Shalaby, M. A., Al‑Mokaddem, A. K., El-Banna, A. H., EL-Banna, H. A., & Nabil, G. (2023) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2023.102234 · Cited by 21
Alzarea, E. A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Beshay, O. N., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08832-6 · Cited by 23
“The causes of AD are aging, environmental toxins, and cardiometabolic factors that induce the degeneration of cholinergic neurons (Breijyeh & Karaman, 2020; Comaposada-Baró et al., 2023).”
Varga, P., Lehoczki, A., Fekete, M., Jarecsny, T., Kryczyk‐Poprawa, A., Zábó, V., Major, D., Fazekas‐Pongor, V., Csípő, T., & Varga, J. T. (2025) · Nutrients · doi:10.3390/nu17132216 · Cited by 23
“Despite extensive research efforts, no effective cure currently exists [132].”
Microbial Metabolomes in Alzheimer’s Disease: From Pathogenesis to Therapeutic Potential
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090724 · Cited by 22
“The etiology of AD remains incompletely understood, with the condition widely recognized as a complex, multifactorial disorder influenced by aging, environmental exposures, and genetic predisposition [5–7].”
Mitochondrial proteotoxicity: implications and ubiquitin-dependent quality control mechanisms
Karbowski, M., Oshima, Y., & Verhoeven, N. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04604-8 · Cited by 23
Singh, S., Chib, S., Akhtar, M. J., Kumar, B., Chawla, P. A., & Bhatia, R. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230105110834 · Cited by 23
“Even with significant advancements in the pharmaceutical field, currently employed drugs in contemporary therapy provides symptomatic treatment and focus on providing improvement in motor ad non-motor symptoms [21-24].”
BackgroundRole of Terpenoids Active Ingredients Targeting for Neuroprotective Agents
Kashyap, N., Kumar, R., Rana, V., Sood, P., & Chauhan, T. (2023) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.2.3.5 · Cited by 21
“1% limonene, was found to demonstrate neuroprotective properties against the neurotoxicity caused by beta-amyloid [115].”
BackgroundKumar, S., Jaiswal, S., Gupta, S. K., & Ayyannan, S. R. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2224887 · Cited by 21
“…aggregation of protein, impaired mitochondrial function and cholinergic neurotrans-mission, iron accumulation, inflammation, oxidative stress and hyperphosphorylation of proteins like tau protein (Breijyeh & Karaman, 2020; Edmondson & Newton-Vinson, 2001; � Ser � y et al., 2013; Wenk, 2003).”
BackgroundPDE4 Inhibitors for Disease Therapy: Advances and Future Perspective
Du, B., Luo, M., Ren, C., & Zhang, J. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0101 · Cited by 21
Bansal, K., Singh, V., Mishra, S., & Bajpai, M. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010265344230919170611 · Cited by 22
The Neuropharmacological Evaluation of Seaweed: A Potential Therapeutic Source
Jannat, K., Balakrishnan, R., Han, J., Yu, Y.-J., Kim, G.-W., & Choi, D. (2023) · Cells · doi:10.3390/cells12222652 · Cited by 23
“The currently available NDD drugs provide only symptomatic relief, primarily by modulating neurotransmission instead of preventing the progression of the disease [5,6].”
BackgroundTalbot, N. C., Luther, P. M., Spillers, N. J., Ragland, A. R., Kidder, E. J., Kelkar, R. A., Varrassi, G., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. D. (2023) · Cureus · doi:10.7759/cureus.50948 · Cited by 25
“AD is one of the most commonly occurring neurodegenerative diseases, marked by amyloid plaques and neurofibrillary tangles [19].”
BackgroundMeng, X., Wu, W., Tang, Y., Peng, M., Jialun, Y., Yuan, S., Hu, Z., & Liu, W. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04067-x · Cited by 21
“AD is one of the most commonly diagnosed diseases worldwide with no known cure, making it a prevalent cause of mortality among patients [1].”
Seifallahi, M., Galvin, J. E., & Ghoraani, B. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230149 · Cited by 21
“Functional status assessment was performed using the Instrumental Activities of Daily Living (IADL) and Activities of Daily Living (ADL) scales, with a cutoff score of ≤6 to differentiate MCI individuals from healthy controls [1].”
MethodAlzheimer’s Disease MRI Classification using EfficientNet: A Deep Learning Model
Aborokbah, M. M. (2024) · International Conference on Applied Artificial Intelligence (ICAPAI) · doi:10.1109/icapai61893.2024.10541281 · Cited by 21
Wojtecki, L., Cont, C., Stute, N., Galli, A., Schulte, C. E., & Trenado, C. (2024) · GeroScience · doi:10.1007/s11357-024-01305-x · Cited by 21
“Focusing on treatments for AD, pharmacological interventions include cholinesterase inhibitors and antagonists to N-methyl-d -aspartate [3] as well as lecanemab and aducanumab, which target the protein beta-amyloid to help reduce amyloid plaques [4, 5].”
Investigating interleukin-8 in Alzheimer's disease: A comprehensive review
Righi, D., Manco, C., Pardini, M., Stufano, A., Schino, V., Pelagotti, V., Massa, F., Stefano, N. D., & Plantone, D. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241298973 · Cited by 22
Martínez‐López, S., Tabone, M., Clemente-Velasco, S., González-Soltero, R., Bailén, M., de Lucas, B., Bressa, C., Domínguez-Balmaseda, D., Marín, J., Antúnez, C., et al. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241292829 · Cited by 24
Bortty, J. C., Chakraborty, G. S., Noman, I. R., Batra, S., Das, J., Bishnu, K. K., Tarafder, M. T. R., & Islam, A. (2025) · Diagnostics · doi:10.3390/diagnostics15060789 · Cited by 21
Functional Genomics of Axons and Synapses to Understand Neurodegenerative Diseases
Paolo, A. D., Garat, J., Eastman, G., Farías, J., Dajas‐Bailador, F., Smircich, P., & Sotelo-Silveira, J. R. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.686722 · Cited by 24
Flores‐Clemente, C., Nicolás‐Vázquez, M. I., Jiménez, E. M., & Rodríguez, M. H. (2021) · Biomolecules · doi:10.3390/biom11101408 · Cited by 21
Anupama, K. P., Olakkaran, S., Antony, A., Raghu, S. V., & Gurushankara, H. P. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.02.011 · Cited by 25
Development of new Alzheimer’s disease drug candidates using donepezil as a key model
Eissa, K. I., Kamel, M. M., Mohamed, L. W., & Kassab, A. E. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202200398 · Cited by 20
Lee, D., Shen, A. M., Shah, M., Garbuzenko, O. B., & Minko, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910357 · Cited by 20
Dignity in people with dementia: A concept analysis
Zhang, Y., Lingler, J. H., Bender, C. M., & Seaman, J. B. (2024) · Nursing Ethics · doi:10.1177/09697330241262469 · Cited by 21
“14 18 Dignity is a complex inherent concept that is a core human right and can provide theoretically driven, value-based direction that should be incorporated as practical guidance for dementia care.”
Lei, K., Zhou, L., Dan, M., Yang, F., Jian, T., Xin, J., Yu, Z., & Wang, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030280 · Cited by 22
“This disease is often accompanied by neuronal damage and β -amyloid protein deposition, leading to a significant decline in the quality of life for patients [75–77].”
Zhang, M., Pan, Y., Cui, Q., Lü, Y., & Yu, W. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112812 · Cited by 20
A Graph Attention Neural Network for Diagnosing ASD with fMRI Data
Yin, W., Li, L., & Wu, F. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669849 · Cited by 23
MiR‐483‐3p improves learning and memory abilities via XPO1 in Alzheimer's disease
Luo, G., Wang, X., & Liu, C. (2022) · Brain and Behavior · doi:10.1002/brb3.2680 · Cited by 21
“Thus, AD can provoke impairments of cardiovascular functions (Yang et al., 2020), and cardiovascular diseases such as neural tissue loss-induced stroke can also be a risk factor for AD (Breijyeh & Karaman, 2020).”
BackgroundQiao, L., Chen, Y., Dou, X., Song, X., & Xu, C. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00590-8 · Cited by 20
“AD is a slowly progressive neurodegenerative disease characterized by the accumulation of neurofibrillary tangles, amyloid plaques, dystrophic neurites, neuropil threads, and synaptic loss (Breijyeh and Karaman 2020).”
BackgroundLiu, L., Yue, H.-Y., Zou, J., Tang, M., Zou, F.-M., Li, Z.-L., Jia, Q., Li, Y., Kang, J., & Zuo, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1076960 · Cited by 22
“It is characterized by classical pathophysiological hallmarks of extracellular accumulating beta-amyloid (Aβ) and intraneuronal tau-laden neurofibrillary tangles (Breijyeh and Karaman, 2020).”
BackgroundDelgorio, P. L., Hiscox, L. V., McIlvain, G., Kramer, M. K., Diano, A., Twohy, K. E., Merritt, A., McGarry, M., Schwarb, H. D., Daugherty, A. M., et al. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103327 · Cited by 27
“Additionally, biological hallmarks, such as amyloid-beta deposition, are associated with tissue atrophy and structural degeneration in aMCI and AD progression (Breijyeh and Karaman, 2020; Gauthier et al., 2006).”
BackgroundTMAO promotes dementia progression by mediating the PI3K/Akt/mTOR pathway
Hu, X., Zhang, Y., Gu, C., Gu, C., Yao, Y., Yao, Y., Luo, L., & Zhang, Y. (2023) · Tissue and Cell · doi:10.1016/j.tice.2023.102034 · Cited by 21
The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer’s Disease Treatment
Knight, E., Geetha, T., Broderick, T. L., & Babu, J. R. (2023) · Metabolites · doi:10.3390/metabo13030438 · Cited by 21
“Since a definitive diagnosis of AD cannot be made without an autopsy, establishing biomarkers for diagnosing AD, particularly in the early phases of the disease, is critical for early diagnosis and detection [7].”
BackgroundInfluentialLo, J., Wu, H., Liu, C., Chang, K., Lee, P., Liu, P., Huang, S., Wu, P., Lin, T.-C., Lai, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087300 · Cited by 21
“Neurodegenerative diseases are prevalent in aging adults worldwide and cause serious health problems by progressive but incurable morbidity, including memory, cognitive and motor impairments [3,4,20].”
BackgroundGeravand, S., Karami, M., Sahraei, H., & Rahimi, F. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176030 · Cited by 21
Formica, C., Bonanno, L., Giambò, F. M., Maresca, G., Latella, D., Marra, A., Cucinotta, F., Bonanno, C., Lombardo, M., Tomarchio, O., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091386 · Cited by 22
“Alzheimer’s disease (AD) is the most common form of neurodegenerative disorder, and it is characterized by a progressive loss of cognitive function, including memory [1,2].”
BackgroundAmadoro, G., Latina, V., Stigliano, E., & Micera, A. (2023) · Cells · doi:10.3390/cells12222601 · Cited by 22
“…Alzheimer’s Disease (AD)—the most prevalent form of neurodegenerative dementia among the elderly with more than 55 million people world-wide [1,2]—and the global pandemic coronavirus disease 2019 (COVID-19), caused by the novel etiological agent known as Severe Acute Respiratory Syndrome…”
BackgroundAbu‐Elfotuh, K., Hamdan, A. M., Mohamed, S. A., Bakr, R. O., Ahmed, A. H., Atwa, A. M., Hamdan, A. M., Alanzai, A. G., Alnahhas, R. K., Gowifel, A. M. H., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117731 · Cited by 22
Quantitative EEG in the Differential Diagnosis of Dementia Subtypes
Olğun, Y., Poyraz, C. A., Bozluolçay, M., & Poyraz, B. Ç. (2024) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887241227410 · Cited by 20
Symptoms and conventional treatments of Alzheimer's disease
Chorawala, M. R., Shah, A. C., Pandya, A. J., Kothari, N. R., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00009-1 · Cited by 21
Muraleedharan, A., & Ray, S. K. (2024) · Brain Sciences · doi:10.3390/brainsci14010096 · Cited by 22
“Alzheimer’s Disease (AD), the most common type of dementia, is known as a neurodegenerative disease caused by the accumulation of amyloid beta (A β ) peptides and tau protein hyperphosphorylation resulting in the formation of neurofibrillary tangles [1,2].”
BackgroundMethodApplications of Raman spectroscopy in the diagnosis and monitoring of neurodegenerative diseases
Chen, C., Qi, J., Li, Y., Li, D., Wu, L., Li, R., Chen, Q., & Sun, N. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1301107 · Cited by 20
Katariya, R., Sammeta, S. S., Kale, M. B., Kotagale, N. R., Umekar, M. J., & Taksande, B. G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102269 · Cited by 22
Parikh, D., & Shah, M. (2024) · Biomedical Analysis · doi:10.1016/j.bioana.2024.05.005 · Cited by 24
Chi, M., Liu, J., Li, L., Zhang, Y., & Xie, M. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c02088 · Cited by 20
Iraji, A., Nikfar, P., Montazer, M. N., Karimi, M., Edraki, N., Saeedi, M., & Mirfazli, S. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-71729-0 · Cited by 22
Townsend, K. L. (2024) · Diabetes · doi:10.2337/dbi24-0004 · Cited by 22
The war against Alzheimer, the mitochondrion strikes back!
Zambrano, K., Barba, D., Castillo, K., Robayo, P., Argueta-Zamora, D., Sanon, S., Arizaga, E., Caicedo, A., & Gavilanes, A. W. D. (2022) · Mitochondrion · doi:10.1016/j.mito.2022.03.003 · Cited by 20
Wang, X., Shuai, W., Yang, P., Liu, Y., Zhang, Y., & Wang, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102584 · Cited by 20
Studying the mechanisms of neurodegeneration: C. elegans advantages and opportunities
Torres, A. K., Mira, R. G., Pinto, C., & Inestrosa, N. C. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1559151 · Cited by 19
Satpathy, B., Rajwar, T. K., Mishra, A. K., Saha, I., Rai, V. K., Sahoo, R. K., Halder, J., Mahanty, R., Manoharadas, S., Al‐Tamimi, J., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05137-4 · Cited by 20
“The Aβ and tau protein synergistically lead to the progression of AD, described by oxidative stress and neuroinflammation [3].”
Tau and Amyloid beta causes microglial activation in Alzheimer’s disease
Chinnathambi, S., Adithyan, A., Chandrashekar, M., & Rangappa, N. (2025) · Advances in clinical chemistry · doi:10.1016/bs.acc.2025.06.002 · Cited by 24
Cerium-based nanoparticles for neurodegeneration: emerging redox therapeutics beyond pharmaceuticals
Mishra, K., Tripathi, S., Tiwari, A. K., Rana, R., Yadav, P., & Chourasia, M. K. (2025) · RSC Advances · doi:10.1039/d5ra03599f · Cited by 20
New progress on the role and mechanism of tau protein in Alzheimer's disease and depression
Wang, Y., Zhou, J., Zhou, Q., & Wang, H. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1551273 · Cited by 22
Microbes in fructooligosaccharides production
Bhadra, S., Chettri, D., & Verma, A. K. (2022) · Bioresource Technology Reports · doi:10.1016/j.biteb.2022.101159 · Cited by 19
The Immune System as a Therapeutic Target for Alzheimer’s Disease
Zieneldien, T., Kim, J., Sawmiller, D. R., & Cao, C. (2022) · Life · doi:10.3390/life12091440 · Cited by 24
“Alzheimer’s disease is characterized by the accumulation of amyloid-beta (Aβ) formed by neuritic plaques and neurofibrillary tangles (NFTs) [9].”
BackgroundInfluentialKwon, O.-Y., & Lee, S. H. (2022) · Antioxidants · doi:10.3390/antiox12010078 · Cited by 19
“To prevent the progress of AD, many studies have focused on finding the central mediators of AD pathogenesis, and as a result, amyloid-β (Aβ) peptide and tau protein have been suggested as primary causes of AD [2].”
BackgroundZhu, J., Liang, Q., He, S., Wang, C., Lin, X., Wu, D., Lin, G., & Wang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1109400 · Cited by 23
“However, these diseases can not be completely cured (The Lancet, 2016), in fact can only be improved by alleviating associated symptoms (Breijyeh and Karaman, 2020).”
BackgroundExploration of novel biomarkers in Alzheimer’s disease based on four diagnostic models
Zou, C., Su, L., Pan, M., Chen, L., Li, H., Zou, C., Xie, J., Huang, X., Lu, M., & Zou, D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1079433 · Cited by 20
“However, these only treat AD symptoms (Breijyeh and Karaman, 2020), and no available treatment can slow or stop the diseases, despite continuous progress in this field.”
BackgroundBhanukiran, K., Singh, S. K., Singh, R., Kumar, A., & Hemalatha, S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00269 · Cited by 20
Getting ahead of Alzheimer’s disease: early intervention with focused ultrasound
Noel, R. L., Gorman, S. L., Batts, A. J., & Konofagou, E. E. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1229683 · Cited by 21
“The etiology of AD is under active investigation and debate (Karran et al., 2011; Breijyeh and Karaman, 2020).”
BackgroundInfluentialSerum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease
Wang, J., Zhou, F., Xiong, C.-E., Wang, G.-P., Chen, L.-W., Zhang, Y., Qi, S.-G., Wang, Z., Mei, C., Xu, Y.-J., et al. (2023) · Aging · doi:10.18632/aging.205015 · Cited by 20
INPP5D/SHIP1: Expression, Regulation and Roles in Alzheimer’s Disease Pathophysiology
Olufunmilayo, E. O., & Holsinger, R. M. D. (2023) · Genes · doi:10.3390/genes14101845 · Cited by 20
“These pathologic l events disrupt cell-to-cell communication, result in the abnormal synthesis and accumulatio of cytoskeletal proteins, contribute to the loss of synapses and exaggerated pruning of dendrites, cause neuronal damage through oxidative metabolism, and eventually lead to cell death [53].”
BackgroundGao, W., Liu, W., Dong, X., & Sun, Y. P. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01763j · Cited by 20
Zhang, J., Chen, Y., Zhao, Y., Wang, P., Ding, H., Liu, C., Lyu, J., & Le, W. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01145-3 · Cited by 19
“To date, the removal of pathogenic proteins or abnormal aggregates (Aβ deposition and hyperphosphorylated tau protein accumulation) in the brain is still the primary option for AD treatment [52].”
BackgroundSu, Z., Yang, Y., Xu, H., Tang, Z., Sun, M., Zhu, Y., Xue, T., He, Y., Wang, H., Yang, H., et al. (2024) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2024.106148 · Cited by 20
Tam, S., Wear, D., Morrone, C. D., & Yu, W. H. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16108 · Cited by 21
“The pathogenesis of AD has been attributed to the aggregation and accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles in the cortical and limbic structures of the brain (Breijyeh & Karaman, 2020; Tiwari et al., 2019).”
Bagrowska, W., Karasewicz, A., & Góra, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104217 · Cited by 22
Elariny, H. A., Kabel, A. M., Selim, H. M. R. M., Helal, A. I., Abdelrahman, D., Borg, H. M., Elkady, M. A., Dawood, L. M., El‐Badawy, M. F., Almalawi, H. F. A., et al. (2024) · Medicina · doi:10.3390/medicina60111805 · Cited by 23
Hosseininasab, S. S. M., Ebrahimi, R., Yaghoobpoor, S., Kazemi, K., Khakpour, Y., Hajibeygi, R., Mohamadkhani, A., Fathi, M., Vakili, K. G., Tavasol, A., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1513095 · Cited by 21
Habibi, F., Ghaderkhani, S., Shokoohi, M., Banari, T., Morsali, M., Abadi, R. N. S., & Kiamehr, H. (2025) · AI and Ethics · doi:10.1007/s43681-025-00673-0 · Cited by 23
“The complexity and multifactorial nature of the disease make it difficult to develop effective treatments [ 15].”
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.